Wilms tumors (WTs) have a complex etiology, displaying genetic and epigenetic changes, including loss of imprinting (LOI) and tumor suppressor gene silencing. To identify new regions of epigenetic perturbation in WTs, we screened kidney and tumor DNA using CpG island (CGI) tags associated with cancer-specific DNA methylation changes. One such tag corresponded to a paralog of the glioma pathogenesis-related 1/ related to testis-specific, vespid, and pathogenesis proteins 1 (GLIPR1/RTVP-1) gene, previously reported to be a tumor-suppressor gene silenced by hypermethylation in prostate cancer. Here we report methylation analysis of the GLIPR1/RTVP-1 gene in WTs and normal fetal and pediatric kidneys. Hypomethylation of the GLIPR1/RTVP-1 5V-region in WTs relative to normal tissue is observed in 21/24 (87.5%) of WTs analyzed. Quantitative analysis of GLIPR1/RTVP-1 expression in 24 WTs showed elevated transcript levels in 16/24 WTs (67%), with 12 WTs displaying in excess of 20-fold overexpression relative to fetal kidney (FK) control samples. Immunohistochemical analysis of FK and WT corroborates the RNA expression data and reveals high GLIPR1/RTVP-1 in WT blastemal cells together with variable levels in stromal and epithelial components. Hypomethylation is also evident in the WT precursor lesions and nephrogenic rests (NRs), supporting a role for GLIPR1/RTVP-1 deregulation early in Wilms tumorigenesis. Our data show that, in addition to gene dosage changes arising from LOI and hypermethylation-induced gene silencing, gene activation resulting from hypomethylation is also prevalent in WTs. Neoplasia (2007) 9, [970][971][972][973][974][975][976][977][978] 
Introduction
Wilms tumor (WT) is the most common solid tumor of childhood and represents a paradigm for tumorigenesis resulting from disrupted development [1] . Germline defects of chromosome 11p13 in Wilms tumor aniridia genitourinary abnormalities, and mental retardation (WAGR) signposted the identification of the tumor-suppressor gene WT1 at this locus [2, 3] , which has subsequently been shown to have loss of function mutations in 5% to 10% of sporadic WTs [4] . More recently, a gene on chromosome Xq11, referred to as WTX, has been shown to be inactivated in about a third of WTs [5] , but for a large proportion of WTs the etiology is undefined.
In addition to genetic events, WT development has been closely linked with epigenetic disturbance, and the phenomenon of loss of imprinting (LOI) was first demonstrated for the IGF2 gene in WTs [6, 7 ] , and has subsequently been shown in a wide spectrum of other cancers [8] . In common with many other cancers, WTs also display two-hit epigenetic gene silencing, i.e., aberrant hypermethylation of tumor-suppressor gene 5V-CpG islands (CGI); examples include RASSF1A (in 42% of tumors) [9] , MCJ (90%), TNFRSF12 (65%) [10] , CASP8 (43%) and MGMT (30%) [11] , and SLIT2 (38%) [12] .
We have also demonstrated WT-specific hypomethylation occurring at the WT1 antisense regulatory region (WT1 ARR) associated with LOI and the increased expression of a putative regulatory RNA, WT1-AS [13] , and an alternative coding transcript, AWT1 [14] . Hypomethylation occurs in a CCCTC binding factor (CTCF)-binding region and is apparent in nephrogenic rests (NRs), suggesting an early impairment of methylation which would normally accompany kidney development, followed by extensive demethylation during expansion of the neoplastic rest and WT [15] . However, although genomewide hypomethylation has long been known to be a common feature of all cancers [16] , examples of genes that are activated by hypomethylation are very scarce compared with genes shown to be silenced by hypermethylation [17, 18] . Examples of genes reportedly activated by hypomethylation include MN/CA9 in renal cell carcinoma [19] , R-RAS in gastric cancers [20] , PAX2 in endometrial carcinomas [21] , and SNCG in a variety of adult cancers [22] . With recent genome analyses suggesting that methylation of CGIs in normal tissue may be more common than previously thought [23] , many more genes may be deregulated by hypomethylation in cancer.
In screens for breast cancer-specific methylation changes using arrayed CGIs, a number of CGI tags were identified as being hypermethylated in breast cancer cell lines and tumor tissues. One such tag, referred to as HBC-2 [24] , was found to correspond to the WT1 ARR that we showed to undergo WT-specific hypomethylation [13] . To identify novel epigenetic changes in WTs, we assessed other CGI tags identified in the breast cancer studies and evaluated the methylation of the corresponding genomic loci. One tag (HBC-1) corresponded to an uncharacterized paralog of the glioma pathogenesisrelated 1/related to testis-specific, vespid, and pathogenesis proteins 1 (GLIPR1/RTVP-1) gene, a proapoptotic p53 target gene [25] . Although it was originally identified as a gene overexpressed in gliomas where it has recently been reported to exert antiapoptotic functions [26, 27] , epigenetic silencing of GLIPR1/RTVP-1 was demonstrated in prostate cancer, implicating it as a putative tumor-suppressor gene [28] . We were therefore prompted to evaluate its epigenetic status in WTs relative to normal fetal and pediatric kidney samples. We present data showing that, contrary to the hypermethylation evident in prostate cancers, GLIPR1/RTVP-1 hypomethylation is prevalent in a high percentage of WTs. High expression of GLIPR1/RTVP-1 is frequently observed in conjunction with hypomethylation. Hypomethylation is also apparent in WT precursor lesions, suggesting it as an early contributory event in Wilms tumorigenesis. Our data suggest that gene activation accompanying hypomethylation of non-imprinted genes is a previously uncharacterized form of epigenetic disruption prevalent in WTs.
Materials and Methods

Patient Samples
All tissues were acquired with appropriate ethical approval as snap frozen samples from the Bristol Children's Hospital and the University of Heidelberg Children's Hospital. WT tissues ranged from stage I to stage V and were obtained along with adjacent histologically normal kidney (NK) and, where available, NRs. Fetal kidney (FK) samples were from 19 to 31 weeks of gestation. A clear cell sarcoma of the kidney (CCSK) was also obtained along with adjacent histologically normal kidney. Details of clinical samples are given in Table 1 . Extraction of total cellular RNA was performed as previously described [29] .
DNA were evaluated for loss of heterozygosity using microsatellite markers D12S1052 and D12S869 on chromosome 12q21. No gains or losses were apparent in informative sam- ples and, therefore, hypomethylation was distinguishable from allele loss.
Methylation Analyses
The HBC-1 sequence (see Figure 1 ) was analyzed using BLAST (www.ncbi.nlm.nih.co.uk/BLAST) and was found to align with the 5V-end of the GLIPR1L1 gene, close to the GLIPR1/RTVP-1 gene on chromosome 12q21 (see Figure 1A ). For combined bisulfite and restriction analysis (COBRA) [30] , genomic DNA were converted using the EZ DNA Methylation-Gold conversion kit (Zymo Research, Orange, CA) according to the manufacturer's instructions. CpGenome universally methylated DNA (Chemicon, Billerica, MA) was used as a positive control for COBRA assays and the following primer and digest combinations were used.
Products were separated by agarose gel electrophoresis and band intensities were quantified using ImageJ software (http:rsb.info.nih.gov/ij/). Bisulfite sequencing used the CO-BRA primers and Hotstart plus Taq (Qiagen, Crawley, UK). Polymerase chain reaction (PCR) products were cloned into pGEMÀ T Easy (Promega, Southampton, UK) or TOPO TA Kit (Invitrogen, Paisley, UK) and positive clones were sequenced.
To generate a larger probe for GLIPR1L1 by Southern blot analysis, the HBC-1 tag was used to screen a genomic library as described previously [31] . A plasmid subclone designated pEBE1.4 was generated from a positive phage clone and its insert was excised and radiolabeled for Southern blot analysis with genomic DNA digested with SacII, EcoRI, and BamHI. Experimental conditions were as previously described [13] .
Reverse Transcriptase -Polymerase Chain Reaction (RT-PCR) Analysis
Total RNA (1 mg) was reverse-transcribed with oligo(dT) 20 at 60jC for 60 minutes using the ThermoScript RT-PCR System (Invitrogen) according to the manufacturer's instructions. RNA complementary to the cDNA was removed by incubating with 2 U RNaseH at 37jC for 20 minutes. cDNA was amplified using 5 ml of a 1:10 dilution of the reverse transcribed cDNA in a 25-ml PCR reaction containing 0.5 U SuperTaq (HT Biotechnology, Cambridge, UK), 0.2 mM each deoxyribonucleotide triphosphate (Sigma, Poole, UK) and 0.3 mM forward and reverse primers. For expression analyses, the following primers were used: GLIPR1, forward primer (5V -AGGCTCCAT-GCCAGACAAAGCATG-3V) and reverse primer (5V -CCTGA-ATTGTATTAGTCCAAAAGAAC-3V); GLIPR1L1, forward primer (5V -CTTTATAGACAACTGACTCGAAGC -3V) and reverse primer (5V -ACCTAATTTCCGACAGACGACTTCCA-3V); and HPRT1, forward primer (5V -CTTGCTGGTGAAAAGGACC-CC-3V) and reverse primer (5V -GTCAAGGGCATATCCTAC-AAC-3V). Thermal cycling consisted of an initial denaturation step of 94jC for 4 minutes and was followed by 35 cycles with denaturation at 94jC for 30 seconds, annealing at 57jC for 30 seconds, and elongation at 72jC for 1 minute and 30 seconds. RT-PCR products were analyzed on a 1% agarose gel. For GLIPR1L1, gels were alkali-blotted onto Hybond-N + membrane and hybridized with 32 P-labeled cDNA probes. Comparative Quantitative Real-Time PCR Real-time PCR was performed using the Stratagene MX3000P QPCR System (La Jolla, CA) along with the Platinum SYBR green qPCR SuperMix-UDG (Invitrogen). Reactions volumes of 20 ml contained 10 ml of Platinum SYBR green qPCR SuperMix-UDG (Invitrogen, Paisley, UK), 50 nM ROX reference dye, 0.2 mM forward primer, 0.2 mM reverse primer, and 0.5 ml of cDNA template. Primers were: GLIPR1, forward primer (5V -GCGTTCGAATCCATAACAAGTTCC-3V) and reverse primer (5V -GGTGGCTTCAGCCGTGTATTAT-GTG -3V); GLIPR1L1, forward primer (5V -AATCCCATCCAT-CACTGACCCACA-3V) and reverse primer (5V -GCCCAT-GCTTTAGCCATCTTTGCT -3V); and MCJ, forward primer (5V -ACCAGCAGGGACTGGTAAGAAGTT-3V) and reverse primer (5V -TTCCAGATCCGAAATGCGTAGCGA-3V). Thermal cycling consisted of an initial incubation step of 50jC for 2 minutes and then a denaturation step of 95jC for 10 minutes. This was followed by 40 cycles of denaturation at 95jC for 15 seconds, annealing at 55jC for 30 seconds, and elongation at 72jC for 30 seconds. A final dissociation curve consisting of denaturation at 95jC for 1 minute, annealing at 55jC for 30 seconds, and elongation at 95jC for 30 seconds was used to identify a single correctly sized product. Gene expression was quantified by comparative C t method, normalizing values to the housekeeping gene TBP or GAPDH and relative to a calibrator. Expression analysis for TBP was performed using forward primer (5V -GCCCGAAACGCCGAATAT -3V) and reverse primer (5V -CCGTGGTTCGTGGCTCTCT -3V) and for GAPDH it was performed using forward primer (5V -GTTCGACAGTCAGCCGCATC-3V) and reverse primer (5V -GGAATTTGCCATGGGTGGA-3V). To ensure experimental accuracy, all reactions were performed in duplicate.
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections for FK and WT were sectioned at 6 mm on poly-L-lysine-coated slides. Immunostaining was carried out as previously reported [28] with the following modifications. Briefly, sections were rehydrated and blocked for endogenous peroxidase activity in 3% H 2 O 2 in methanol. Following microwave antigen retrieval using citrate buffer, samples were blocked with 5% normal goat serum. An additional avidin/biotin blocking step was used to eliminate further endogenous biotin (Dako, Ely, UK). RTVP-1 primary antibody (a kind gift from Dr. T. Thompson, Baylor College of Medicine, TX) was diluted 1 in 2000 in phosphate-buffered saline and was incubated at room temperature for 4 hours. The secondary antibody was biotinylated goat anti-rabbit followed by horseradish peroxidase streptavidin (Dako). Visualization was with the DAB -substrate chromogen system (Dako).
5-Aza-2 V-Deoxycytidine (AZA) Treatment
Anaplastic WT-derived cell lines 17.94 (Brown, unpublished observations) and WiT49 were treated 24 hours after seeding with 5 mM of the DNA methylation inhibitor AZA (Sigma)
Results
Hypomethylation of GLIPR1/RTVP-1 in WTs
The CGI tag, HBC-1, which undergoes tumor-specific hypermethylation in breast tumors [24] , was found to correspond to the 5V-end of the GLIPR1L1 gene. Methylation changes for this gene are described briefly below, but as nothing is known of GLIPR1L1 function, and expression of this gene is low or absent in renal samples, it was not focused on. The GLIPR1L1 gene is located in a paralog cluster on chromosome 12q21 (see Figure 1A ) [32] , which includes GLIPR1L2 and GLIPR1/RTVP-1. As GLIPR1/RTVP-1 has been reported to have pro-and antiapoptotic activities [25, 27] , and the gene was silenced by hypermethylation in cancer [28] , it was analyzed in detail.
We assessed methylation of the GLIPR1/RTVP-1 gene in WTs using COBRA across CpGs shown to affect expression (sites I, K, and L according to Ren et al. [28] ) (see Figure 1B) . Whereas matched FKs (n = 3) and NKs (n = 17) exhibited considerable methylation of the GLIPR1/RTVP-1 gene 5V-region, 21/24 WTs (87.5%) displayed extensive hypomethylation (see Figure 2A) . One of the three FK samples assayed is shown, and one of the three WTs without hypomethylation (sample 61). Triphasic WTs, blastemal-rich WTs, and stromal predominant WTs (see Table 1 ) were all represented in the analysis and showed similar hypomethylation. We also observed a similar pattern in CCSK (sample 23). As COBRA encompasses only three CpG dinucleotides, we further assessed methylation changes using bisulfite sequencing. This confirmed that methylation was widespread in FK and NK at CpGs F -L (see Figure 1B) , but virtually absent in WT (see Figure 2B ).
Overexpression of GLIPR1/RTVP-1 in WTs
We analyzed 5 FK RNA, 18 NK RNA, and 24 WTs for GLIPR1/RTVP-1 transcripts by quantitative RT-PCR, and representative results are shown in Figure 3A . Six NK samples (five fetal and one pediatric kidney) are shown on the left of the histogram, followed by six matched NK/WT pairs, and six WTs with characterized WT1 mutations on the right [33] . Of the latter ANS2 had triphasic histology and the remainder were stromal predominant WTs (see Table 1 ). Five of the six tumors with matched NK showed GLIPR1/RTVP-1 expression levels elevated 17-to 150-fold relative to 19-week-old FK, and the stromal predominant WTs showed 11-to 40-fold increases. Interestingly, tumor 62, despite exhibiting clear hypomethylation (see Figure 2A) , expressed approximately 80% less GLIPR1/RTVP-1 than the matched NK, the only tumor to show this pattern. This tumor is an anaplastic WT with a p53 mutation, and the lowered GLIPR1/RTVP-1 expression in this sample is consistent with p53 being an activator of the GLIPR1/RTVP-1 gene transcription [25] . Of 16 WTs where adjacent NK was also assessed, this was the only sample with Figure 3B and median expression levels for the three sample sets were 4.8 (FKs), 3.5 (NKs), and 21.9 (WTs). Sixteen of 24 WTs expressed GLIPR1/ RTVP-1 transcripts levels higher than the FK median. As previously shown [28] , demethylation induced by treating cultured cells with AZA was found to increase GLIPR1/RTVP-1 expression ( Figure 3C ). Wilms tumors arise during embryonic kidney development and it is therefore imperative to evaluate molecular changes in WTs relative to FK. Expression of GLIPR1/RTVP-1 protein was assessed in these tissues using an anti -GLIPR1/RTVP-1 antibody previously used in analysis of prostate cancers [28] . Immunohistochemical staining of FK sections demonstrated nuclear expression of GLIPR1/RTVP-1 in epithelial cells of the primitive glomeruli and fainter expression in the blastema at the kidney edge, together with weak cytoplasmic staining in primitive tubules (see Figure 4) . In a triphasic WT, GLIPR1/RTVP-1 was strongly expressed in blastemal cells, mainly in the cytoplasm. Staining in epithelial and stromal elements can be observed but was weaker or absent compared to the blastemal cells. Crucially, the tumor blastemal cells clearly expressed higher GLIPR1/RTVP-1 than the FK blastemal cells. Together with the methylation analysis, our RNA and protein expression data strongly suggests that GLIPR1/RTVP-1 is induced by hypomethylation in WTs.
Hypomethylation Is an Early Event in Wilms Tumorigenesis
The preceding analyses strongly suggests that hypomethylation of specific genes in WTs can lead to their overexpression. However, it is uncertain whether such changes are a cause or consequence of tumor development. We therefore assessed the methylation status of GLIPR1/ RTVP-1 in WT precursor lesions and NRs. Figure 5 shows COBRA of a NK, WT, and NR set (patient 65), together with a second rest (patient 62). Both left and right tumors from patient 65 showed hypomethylation, and the NR showed partial hypomethylation (see Figure 5, A and B) . A second NR from a different patient (62) showed comparable methylation to the patient 65 rest. These results are indicative of an early progressive decrease in gene-specific methylation during Wilms tumorigenesis or an expansion of cells with GLIPR1/RTVP-1 hypomethylation.
GLIPR1/RTVP-1 Methylation Changes Are Specific and Not Regional
We used the HBC-1 tag to subclone a single-copy probe spanning the GLIPR1L1 5V-end to assess DNA methylation at a region proximal to GLIPR1/RTVP-1 (see Figure 6A ). As shown in Figure 6C , two major bands were apparent in 
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normal tissue DNA, corresponding in size to fragments digested (975 bp) and undigested (1410 bp) at the SacII site within GLIPR1L1 exon 1. Figure 6C (top panel) shows that 7/15 WTs examined had hypomethylation relative to the apparent differential methylation observed with normal DNA. A further 3/15 WTs showed no changes relative to their adjacent NK (patients 83, 86, and 69) and 5/15 of patient samples analyzed displayed apparent hypermethylation of GLIPR1L1.
The Southern blot analysis of normal tissues and WTs representing hyper-and hypomethylated subsets was confirmed by bisulfite sequencing (see Figure 6D ). Methylation in normal tissues was highly restricted in the region of the SacII site and reflected the pattern of differential methylation observed by Southern blot analysis. One of the panel of tumors showing hypomethylation in Figure 6C , WT72, showed virtually no methylation, whereas bisulfite sequencing of WT81 was in accord with Southern blot data, displaying increased methylation relative to normal tissues. Thus, in contrast to GLIPR1/ RTVP-1, GLIPR1L1 appeared consistently and differentially methylated in normal tissues and displayed very variable methylation patterns in WTs. Importantly, the epigenetic heterogeneity at this locus suggests that the high frequency of hypomethylation observed for GLIPR1/RTVP-1 is not merely a reflection of locus or cell type -specific methylation changes, as many samples that show hypomethylation at GLIPR1/ RTVP-1 do not show hypomethylation at GLIPR1L1 (compare samples 24, 61, 63, 69, 83, and 85 in Figures 2A and 6C ). We assessed GLIPR1L1 transcript levels in kidney and WT samples and, although expression was too low to detect by RT-PCR, very low levels could be detected after Southern blot analysis and hybridization with radioactive probes in six patient samples (see Figure 6E ). All other samples were negative. Although WTs appear to express higher levels of GLIPR1L1 than kidney controls, the expression did not correlate with methylation status, as samples with tumor hypermethylation (61, 81, and 85) and hypomethylation (28, 57, and 72) had detectable GLIPR1L1.
Discussion
The analysis of tumor-suppressor gene silencing in cancer cells is a major focus of contemporary cancer research. However, there is increasing evidence that gene activation associated with hypomethylation is involved in cancer. Examples include PAX2 activation in endometrial carcinomas [21] and SNCG activation in a wide variety of human cancers [22] .
In this report, we show for the first time that hypomethylationassociated gene activation of nonimprinted genes is found in WT, with the GLIPR1/RTVP-1 gene displaying deregulated expression in tumors relative to normal fetal and pediatric kidney. Furthermore, we demonstrate that altered methylation is detectable in WT precursor lesions, suggesting that these changes occur early and may contribute to tumorigenesis. Our methylation analysis of GLIPR1/RTVP-1 reveals remarkably frequent tumor-specific hypomethylation of the gene, apparent in 87.5% of WTs (n = 24). By way of comparison, R-RAS analysis showed partial hypomethylation in 3/5 primary gastric [20] . Also, whereas a large study of the SNCG in adult cancers demonstrated hypomethylation of this gene in all tumors (n = 20 per tumor), hypomethylation was also observed in 30% of normal adjacent tissue [22] , in contrast to our findings of highly tumor-specific hypomethylation. GLIPR1/ RTVP-1 has already been shown to be epigenetically altered (hypermethylated) in prostate cancer, and it will clearly be of great interest to evaluate its epigenetic status in other cancers.
GLIPR1/RTVP-1 has been shown to be a p53-regulated proapoptotic tumor-suppressor gene undergoing epigenetic silencing in prostate cancer [25, 28] . However, in glioma cells, GLIPR1/RTVP-1 expression is high [26, 27] . Quantitative mRNA analysis revealed that GLIPR1/RTVP-1 levels were approximately 3-fold higher in low-grade astrocytomas compared to normal brain, with glioblastomas being 8-fold higher. Strikingly, our expression analysis of WTs shows that over half express mRNA levels in excess of 20-fold relative to FK, with some even exceeding 100-fold. In all, 16 WTs showed elevated expression levels, whereas 8 did not; of the latter, 2 displayed no hypomethylation, and 1 tumor had a p53 mutation. Hence, for 5 of 24 tumors, there was no direct correlation between methylation/genetic factors and GLIPR1/ RTVP-1 expression. Similar results have been observed for other genes undergoing hypomethylation such as SNCG [22] , where approximately 30% of tumors did not show a methylation/expression correlation. This is likely attributable to the absence or alteration of other cellular proteins which may be necessary for high-level expression of GLIPR1/ RTVP-1. Concomitant requirement for hypomethylation and upregulation of the transcription factor early growth response-1 has been reported for heparanase gene overexpression in prostate [34] and bladder cancers [35] .
In glioma cells, the GLIPR1/RTVP-1 protein positively regulates growth, survival, and invasion. GLIPR1/RTVP-1 overexpression results in elevated Bcl2, leading to an antiapoptotic effect, and increases the activity of matrix metalloproteinase-2, thereby positively regulating the invasive potential of glioma cells [27] . We also note that the scl-1 gene in Caenorhabditis elegans, which is homologous to GLIPR1/RTVP-1, has been shown to encode a regulator of longevity and stress resistance [36] . Our methylation analysis of GLIPR1/RTVP-1 revealed tumor-specific hypomethylation and overexpression relative to FK and NK in WTs. Although the biologic roles of GLIPR1/RTVP-1 in WT cells remain to be elucidated, it is plausible that, as in the case of gliomas, GLIPR1/RTVP-1 exerts a proliferative, prosurvival influence.
Our recent study of epigenetic deregulation of AWT1/ WT1-AS in WTs showed that LOI is an early event in Wilms tumorigenesis [15] . Hypomethylation of GLIPR1/RTVP-1 is apparent in NRs and in left and right tumors where WT is bilateral. Although the progressive increase in hypomethylation seen in NRs might be considered to simply reflect an expansion of oncofetal cells, our previous work argues against this as methylation at the WT1 ARR in NRs shows a general increase relative to FK [15] . Therefore, the early gene-specific hypomethylation reported for GLIPR1/RTVP-1 may contribute to Wilms tumorigenesis, rather than merely accompanying tumorigenesis. This is supported by our immunohistochemical analysis showing that WT blastemal cells express very high levels of GLIPR1/RTVP-1 compared to FK blastemal cells. Overexpression of GLIPR1/RTVP-1 in WT may serve as a useful diagnostic marker, although therapeutic use may be complicated by GLIPR1/RTVP-1 expression seemingly required for NK development and function.
Our methylation analysis of GLIPR1L1 further supports the contention that GLIPR1/RTVP-1 methylation changes in WT are specific and not just regional. Our preliminary analysis also shows that the GLIPR1L2 gene does not undergo epigenetic alterations in WT (data not shown). Although some methylation changes are observed at the GLIPR1L1 gene, they are inconsistent and do not correlate with expression. Expressions of GLIPR1L1 by Northern blot analysis (data not shown) and by quantitative RT-PCR [32] show that it is highly expressed in the testis with little or no expression in other tissues. This highly restricted expression pattern, together with the expression shown here in tumors, suggests that GLIPR1L1 can be considered a cancer-testis gene. Cancertestis proteins are only found in a minor subset of cells within a tumor and it has been suggested that they may serve as a marker for cancer stem cells [37] . Thus, although GLIPR1L1 expression was very low in WT samples, it may yet be a valuable target for immunotherapy against cancer stem cells.
Finally, given that a recent analysis of the human genome suggests that methylation of non-CGI upstream regions is relatively common [23, 38] , our study underlines the need for extensive analysis of gene activation by hypomethylation and emphasizes an important caveat for cancer therapies using DNA methylation inhibitors, because these may inappropriately activate tumor-promoting genes.
